Drugs / Proparacaine
Proparacaine
also known as
Proparacaine Hydrochloride · proparacaine HCl · Proxymetacaine · Alcaine · Ak-taine · Kainair · NSC-759896 · Ophthaine · +4 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OPHTHAINE | — | 1953-07-01 | fda.gov ↗ |
Trials 10
19521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00620997 | Oct 2005 → Sep 2006 | corneal disorder | London Health Sciences Centre | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01027611 | Oct → Nov 2009 | — | Illinois Retina Associates | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05663684 | Jun 2020 → Dec 2022 overdue | dacryocystitis, excessive tearing, lacrimal duct obstruction | Louisiana State University Health Sciences Center in New Orleans | Recruiting | No outcome recorded |
| Phase 4 | NCT04229771 | Jun → Nov 2020 | dacryocystitis, excessive tearing, stenosis of lacrimal passage | Corewell Health East | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04283331 | Jun 2020 → Dec 2021 | astigmatism, hyperopia, myopia | Beeran Meghpara, MD | Unknown | No outcome recorded |
| Phase not applicable5 trials · 1 missed | ||||||
| — | NCT02951351 | Oct 2016 → Feb 2018 | age-related macular degeneration, diabetic macular edema | Mayo Clinic | Completed | No outcome recorded |
| — | NCT03049163 | Oct 2016 → Mar 2017 | — | Lin Zhong | Unknown | No outcome recorded |
| — | NCT02973581 | Feb 2016 → Feb 2017 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT01266824 | Dec 2010 → Aug 2011 | retinopathy of prematurity | Children's Hospital of Philadelphia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00769392 | Sep 2008 → Aug 2009 | macular degeneration | Lahey Clinic | Completed | Missed primary |
| Comparator or background therapy12 trials | ||||||
| Phase 3 | NCT05325853 Comparator | Apr → May 2022 | — | American Genomics, LLC | Completed | Met primary |
| Phase 4 | NCT07456826 Comparator | Mar → Aug 2026 overdue | age-related macular degeneration, diabetic macular edema, retinal vein occlusion | Harrow Inc | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06636708 Background | Dec 2024 → Apr 2025 | corneal disorder | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT05238233 Background | Apr 2022 → Jan 2023 | anisocoria | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 4 | NCT04346095 Background | Jun → Oct 2020 | lens disorder, macular holes, preretinal fibrosis, retinal detachment +1 | Rocky Vista University, LLC | Unknown | No outcome recorded |
| — | NCT04102878 Comparator | Jun → Oct 2019 | eyelid disorder | University Hospital Southampton NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT02925832 Background | Oct → Dec 2016 | cataract | Government Medical College, Haldwani | Completed | No outcome recorded |
| — | NCT02528123 Background | Apr 2016 → Dec 2020 | myopia | London Vision Clinic | Completed | No outcome recorded |
| — | NCT02613013 Background | Oct 2015 → Mar 2020 | primary angle-closure glaucoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02895074 Background | Aug 2014 → Jun 2015 | cataract | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT02609997 Background | Sep → Dec 2012 | cataract | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01640171 Background | Jul 2012 → Sep 2013 | age-related macular degeneration, central retinal vein occlusion, diabetic macular edema | Retina Vitreous Associates of Florida | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-01 | Alcon Research | Alcon Broadens Ophthalmic Solutions with Addition of Topical Local Anesthetic: ALCAINE® (proparacaine hydrochloride ophthalmic solution, USP) 0.5% 15mL alcon.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | proparacaine | “The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗ |
| Known as | Ak-taine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | Alcaine | “Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery” NCT02609997 ↗1“vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]” NCT03049163 ↗ |
| Known as | Kainair | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | NSC-759896 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | Ophthaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | Ophthetic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | Paracaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | proparacaine HCl | “This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.” NCT06636708 ↗2“vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]” NCT03049163 ↗ “proparacaine HCL 0.5%” NCT01027611 ↗ |
| Known as | Proparacaine Hydrochloride | “The three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, Akorn, Inc), 2) 0.5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4%...” NCT01027611 ↗6“Topical proparacaine hydrochloride ophthalmic solution 0.5% administered as 3 drops to the study eye prior to intravitreal injection.” NCT07456826 ↗ “Proparacaine Hydrochloride ophthalmic solution, USP 0.5%” NCT05663684 ↗ “Drug: Proparacaine Hydrochloride” NCT05238233 ↗ |
| Known as | Proximetacaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Known as | Proxymetacaine | “Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied” NCT04102878 ↗ |
| Known as | Proxymetacaine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1196 ↗ |
| Modality | Other / unclassified | “Local anesthetic” NCT02925832 ↗ |
| Route | Topical | “topical, 0.05% drops, PRN continuously for up to 7 days” NCT00620997 ↗ |